Evommune (EVMN) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Evommune (EVMN) over the past year, losing 38.6% versus a loss of 62.4%. Evommune is the larger company by market cap ($291.1 million vs $279.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | RLMD |
|---|---|---|
| Share price | $7.04 | $2.62 |
| Market cap | $291.10M | $279.54M |
| 1-day change | -2.76% | -15.76% |
| YTD return | -58.88% | -45.76% |
| 1-year return | -62.37% | -38.64% |
| 5-year return | — | -86.09% |
| EPS (TTM) | $-3.83 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.00M | — |
| Revenue growth (YoY) | +85.71% | — |
| Net income (latest FY) | $-68.87M | $-57.39M |
| Operating margin | -623.62% | — |
| Net margin | -529.77% | — |
| 52-week high | $33.20 | $8.00 |
| 52-week low | $4.94 | $2.60 |
| Distance from 52-week high | -78.80% | -67.25% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +210.94% | +310.31% |
| Average volume | 841.65K | 1.45M |
| Shares outstanding | 41.35M | 106.69M |
| Employees | 48 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed EVMN by 23.7 percentage points over the past year.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
EVMN vs RLMD FAQ
Which is bigger, Evommune or Relmada Therapeutics?
Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $279.54M for Relmada Therapeutics (RLMD).
Which stock has performed better over the past year, EVMN or RLMD?
RLMD returned -38.64% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.
Are Evommune and Relmada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.